by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
by Jason Heaviland | Dec 17, 2025 | Uncategorized
The Critical Challenge of Model Validation in Alzheimer’s Drug Development The pharmaceutical industry faces a persistent challenge in neurodegenerative disease research: ensuring that preclinical models accurately recapitulate the complex biochemical landscape...
by Jason Heaviland | Dec 2, 2025
Beyond Plaques and Tangles: How Untargeted Metabolomics Detects Distinct Signatures in Alzheimer’s Disease Untargeted metabolomics captures systemic metabolic changes in neurodegenerative diseases, such as Alzheimer’s, identifying altered pathways and...
by Jason Heaviland | Nov 4, 2025 | Uncategorized
The Metabolic Frontier of Neuroscience: Lessons from Alzheimer’s Disease Alzheimer’s disease is a complex, devastating neurodegenerative disorder and the most common form of dementia, affecting millions globally. While decades of research have focused on the infamous...
